F. Hoffmann-La Roche Ltd: Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
25.8
DFS, HR
(95% CI)
(0.19-0.60)
About bladder cancer and muscle-invasive urothelial cancer
In 2018, there were over half a million new cases of bladder cancer diagnosed globally, with approximately 200,000 deaths from the disease.
4 Urothelial cancer is the most common type of bladder cancer, accounting for about 90-95% of all cases.
5 MIUC is a type of urothelial cancer that has spread into the muscle of the bladder, ureter or renal pelvis.
6 Approximately 25% of new cases of bladder cancer are diagnosed with muscle-invasive disease,
F. Hoffmann-La Roche Ltd
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with those without ctDNA
The goal of current treatment in people with MIUC is to provide early intervention to reduce the risk of the disease recurring or spreading to other parts of the body